Vanda Pharmaceuticals Inc logo

Vanda Pharmaceuticals Inc

FRA:VM4 (USA)   Ordinary Shares
€ 4.40 (+1.85%) Dec 20
At Loss
P/B:
0.50
Market Cap:
€ 261.63M ($ 272.32M)
Enterprise V:
€ -91.50M ($ -95.24M)
Volume:
150.00
Avg Vol (2M):
1.35K
Trade In:
Volume:
150.00
At Loss

Business Description

Vanda Pharmaceuticals Inc logo
Vanda Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
ISIN : US9216591084

Share Class Description:

FRA:VM4: Ordinary Shares
Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Name Current Vs Industry Vs History
Cash-To-Debt 47.39
Equity-to-Asset 0.84
Debt-to-Equity 0.02
Debt-to-EBITDA -0.26
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.05
Distress
Grey
Safe
Beneish M-Score -1.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 47.97
9-Day RSI 44.24
14-Day RSI 45.07
6-1 Month Momentum % -17.86
12-1 Month Momentum % 24.32

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.85
Quick Ratio 4.84
Cash Ratio 4.22
Days Inventory 41.65
Days Sales Outstanding 70.67
Days Payable 138.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.6
Shareholder Yield % 0.67

Financials (Next Earnings Date:2025-02-07 Est.)

FRA:VM4's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Vanda Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 175.003
EPS (TTM) (€) -0.256
Beta 0.04
Volatility % 47.68
14-Day RSI 45.07
14-Day ATR (€) 0.091038
20-Day SMA (€) 4.557
12-1 Month Momentum % 24.32
52-Week Range (€) 3.18 - 6.1
Shares Outstanding (Mil) 58.31

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vanda Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Vanda Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Vanda Pharmaceuticals Inc Frequently Asked Questions

What is Vanda Pharmaceuticals Inc(FRA:VM4)'s stock price today?
The current price of FRA:VM4 is €4.40. The 52 week high of FRA:VM4 is €6.10 and 52 week low is €3.18.
When is next earnings date of Vanda Pharmaceuticals Inc(FRA:VM4)?
The next earnings date of Vanda Pharmaceuticals Inc(FRA:VM4) is 2025-02-07 Est..
Does Vanda Pharmaceuticals Inc(FRA:VM4) pay dividends? If so, how much?
Vanda Pharmaceuticals Inc(FRA:VM4) does not pay dividend.

Press Release

Subject Date
No Press Release